» Articles » PMID: 3459930

Mortality and Cancer Incidence in 263 Patients with Ataxia-telangiectasia

Overview
Specialty Oncology
Date 1986 Jul 1
PMID 3459930
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Mortality and cancer incidence were measured retrospectively in 263 ataxia-telangiectasia (A-T) homozygotes. For white and black A-T patients, respectively, all-cause mortality was 50 and 147 times higher than expected based on U.S. mortality rates. There were 52 primary cancers, representing a 61-fold cancer excess for white probands and a 184-fold excess for black probands. The cancer excess was most pronounced for lymphoma, with 252- and 750-fold excesses observed for whites and blacks, respectively. All the age-specific mortality and cancer incidence rates for blacks exceeded those for whites, and overall mortality was 3.0 times higher for black probands than for whites (P less than .001), whereas cancer incidence was 2.2 times higher (P less than .06). Among the white A-T patients, 36% of those who had died had lived at least until 20 years of age, and 33% of those still living were at least 20 years old.

Citing Articles

The Development of ATM Inhibitors in Cancer Therapy.

Ampolini E, Jimenez-Sainz J, Long D Target Oncol. 2025; .

PMID: 40024979 DOI: 10.1007/s11523-025-01136-6.


ATM in immunobiology: From lymphocyte development to cancer immunotherapy.

Lee J Transl Oncol. 2025; 52():102268.

PMID: 39752906 PMC: 11754496. DOI: 10.1016/j.tranon.2024.102268.


Breast cancer and ATM mutations: treatment implications.

Seca M, Narod S Hered Cancer Clin Pract. 2024; 22(1):26.

PMID: 39543654 PMC: 11566136. DOI: 10.1186/s13053-024-00300-9.


Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis.

Fekrvand S, Abolhassani H, Esfahani Z, Fard N, Amiri M, Salehi H J Clin Immunol. 2024; 45(1):34.

PMID: 39466473 DOI: 10.1007/s10875-024-01810-w.


The Gut Connection: Exploring the Possibility of Implementing Gut Microbial Metabolites in Lymphoma Treatment.

Al-Khazaleh A, Chang D, Munch G, Bhuyan D Cancers (Basel). 2024; 16(8).

PMID: 38672546 PMC: 11048693. DOI: 10.3390/cancers16081464.